Literature DB >> 6109601

Tyrosine transaminase activity in normal and cirrhotic liver.

J M Henderson, B A Faraj, F M Ali, D Rudman.   

Abstract

Most cirrhotics have tyrosinemia and subnormal tyrosine tolerance; in some the ability to metabolize p-hydroxyphenylpyruvic and homogentisic acids is impaired. In previous studies, the initial transamination appeared to be the rate-limiting step. In this study, hepatic tyrosine transaminase activity was compared in liver biopsies from eight noncirrhotic and ten cirrhotic subjects to determine whether the subnormal tyrosine tolerance was related to decreased maximal activity of this enzyme. Fasting plasma tyrosine in the cirrhotics (133 +/- 43 micromol/liter) was significantly higher (P less than 0.005) than in the noncirrhotic subjects (64 +/- 25 micromol/liter). Tyrosine transaminase activity in the cirrhotic livers (42 +/- 11 micromol PHPA/g liver/hr, or 0.47 +/- 0.1 micromol PHPA/mg protein/hr) was not significantly different from the enzyme activity in the noncirrhotic liver (43 +/- 7 micromol PHPA/g liver/hr, or 0.39 +/- .12 micromol PHPA/mg protein/hr.) Thus elevated tyrosine levels in cirrhotics cannot be explained by decreased tyrosine transaminase activity in the liver, and other explanations must be sought.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6109601     DOI: 10.1007/bf01312228

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  A new error of tyrosine metabolism: tyrosinosis. The intermediary metabolism of tyrosine and phenylalanine.

Authors:  G Medes
Journal:  Biochem J       Date:  1932       Impact factor: 3.857

2.  Quantitative tests of nitrogen metabolism in cirrhosis: relation to other manifestations of liver disease.

Authors:  J D Ansley; J W Isaacs; L F Rikkers; M H Kutner; B M Nordlinger; D Rudman
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

3.  False neurotransmitters and hepatic coma.

Authors:  J E Fischer
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1974

4.  Vitamin B6 metabolism in chronic alcohol abuse. Pyridoxal phosphate levels in plasma and the effects of acetaldehyde on pyridoxal phosphate synthesis and degradation in human erythrocytes.

Authors:  L Lumeng; T K Li
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

5.  Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography.

Authors:  S B Heymsfield; T Fulenwider; B Nordlinger; R Barlow; P Sones; M Kutner
Journal:  Ann Intern Med       Date:  1979-02       Impact factor: 25.391

6.  Soluble and mitochondrial forms of tyrosine aminotransferase. Relationship to human tyrosinemia.

Authors:  J H Fellman; P J Vanbellinghen; R T Jones; R D Koler
Journal:  Biochemistry       Date:  1969-02       Impact factor: 3.162

7.  Liver panangiography in the assessment of portal hypertension in liver cirrhosis.

Authors:  M Viamonte; W D Warren; J J Fomon
Journal:  Radiol Clin North Am       Date:  1970-04       Impact factor: 2.303

8.  Tyramine kinetics and metabolism in cirrhosis.

Authors:  B A Faraj; J T Fulenwider; E B Rypins; B Nordlinger; G L Ivey; R D Jansen; F M Ali; V M Camp; M Kutner; F Schmidt; D Rudman
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

9.  Microassay of tyrosine-amino transferase and p-hydroxyphenylpyruvic acid oxidase in mammalian liver and patients with hereditary tyrosinemia.

Authors:  D T Whelan; V G Zannoni
Journal:  Biochem Med       Date:  1974-01

10.  The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver.

Authors:  D H Williamson; P Lund; H A Krebs
Journal:  Biochem J       Date:  1967-05       Impact factor: 3.857

View more
  1 in total

1.  Total parenteral nutrition with F080 in cirrhotics with subclinical encephalopathy.

Authors:  W J Millikan; J M Henderson; W D Warren; S P Riepe; M H Kutner; L Wright-Bacon; C Epstein; R B Parks
Journal:  Ann Surg       Date:  1983-03       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.